A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
this is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and
pharmacokinetics of HYLM-122 monotherapy in Chinese subjects with FLT3 positive relapsed or
refractory acute myeloid leukemia.